While these studies have provided support for existing schizophrenia drug targets, such as the dopamine 2 receptor (DRD2), they also offer an opportunity to identify drug targets which are not dependent on prior hypotheses of schizophrenia pathophysiology or the mechanisms of action of existing drugs. This evidence concerns the gene DRD2 and schizophrenia.